Bayer (Schweiz) AG - rezultati pretrage

bayer ag - riociguat - hypertensio, keuhkokuume - keuhkoverenpainetaudin verenpainelääkkeet - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. teho on osoitettu in pah väestöön, mukaan lukien etiologia idiopaattinen tai periytyviä pah-yhdisteiden tai pah-yhdisteiden liittyy sidekudoksen sairaus. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Finska - finski - Fimea (Suomen lääkevirasto)

adalat 20 mg depottabletti

bayer ag - nifedipinum - depottabletti - 20 mg - nifedipiini

Finska - finski - Fimea (Suomen lääkevirasto)

adalat 10 mg depottabletti

bayer ag - nifedipinum - depottabletti - 10 mg - nifedipiini

Finska - finski - Fimea (Suomen lääkevirasto)

syscor 10 mg depottabletti

bayer ag - nisoldipinum - depottabletti - 10 mg - nisoldipiini